Comment

. 2018 Oct 1;102(2):233-242.

doi: 10.1016/j.ijrobp.2018.05.026.

Gastrointestinal Cancers-Carving Out the Optimal Local Therapies in the Gastrointestinal Tract

Jeffrey R Olsen¹, James D Murphy², Florence Huguet³, Christopher L Hallemeier⁴, Smith Apisarnthanarax⁵, Salma K Jabbour⁶

Affiliations

¹ Department of Radiation Oncology, University of Colorado, Denver, Colorado.
² Department of Radiation Medicine and Applied Sciences, University of California San Diego, San Diego, California.
³ Department of Radiation Oncology, Tenon Hospital, Paris Sorbonne University, Paris, France.
⁴ Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
⁵ Department of Radiation Oncology, Seattle Cancer Care Alliance, University of Washington, Seattle, Washington.
⁶ Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, New Jersey. Electronic address: jabbousk@cinj.rutgers.edu.

PMID: 30191854
PMCID: PMC11101013
DOI: 10.1016/j.ijrobp.2018.05.026

Comment

Gastrointestinal Cancers-Carving Out the Optimal Local Therapies in the Gastrointestinal Tract

Jeffrey R Olsen et al. Int J Radiat Oncol Biol Phys. 2018.

. 2018 Oct 1;102(2):233-242.

doi: 10.1016/j.ijrobp.2018.05.026.

Authors

Jeffrey R Olsen¹, James D Murphy², Florence Huguet³, Christopher L Hallemeier⁴, Smith Apisarnthanarax⁵, Salma K Jabbour⁶

Affiliations

¹ Department of Radiation Oncology, University of Colorado, Denver, Colorado.
² Department of Radiation Medicine and Applied Sciences, University of California San Diego, San Diego, California.
³ Department of Radiation Oncology, Tenon Hospital, Paris Sorbonne University, Paris, France.
⁴ Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
⁵ Department of Radiation Oncology, Seattle Cancer Care Alliance, University of Washington, Seattle, Washington.
⁶ Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, New Jersey. Electronic address: jabbousk@cinj.rutgers.edu.

PMID: 30191854
PMCID: PMC11101013
DOI: 10.1016/j.ijrobp.2018.05.026

Erratum in

Erratum to: Olsen JR, Murphy JD, Huguet F, et al. Oncology Scan: Gastrointestinal Cancers - Carving Out the Optimal Local Therapies in the Gastrointestinal Tract. Int J Radiat Oncol Biol Phys 2018;102:233-242.
[No authors listed] [No authors listed] Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):286. doi: 10.1016/j.ijrobp.2018.09.030. Epub 2018 Dec 12. Int J Radiat Oncol Biol Phys. 2019. PMID: 30563664 No abstract available.

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Dr. Jabbour has research funding from Nestle and Merck unrelated to this work.

Comment on

Short-Course Radiotherapy Followed by Neoadjuvant Bevacizumab, Capecitabine, and Oxaliplatin and Subsequent Radical Treatment in Primary Stage IV Rectal Cancer: Long-Term Results of a Phase II Study.
Bisschop C, van Dijk TH, Beukema JC, Jansen RLH, Gelderblom H, de Jong KP, Rutten HJT, van de Velde CJH, Wiggers T, Havenga K, Hospers GAP. Bisschop C, et al. Ann Surg Oncol. 2017 Sep;24(9):2632-2638. doi: 10.1245/s10434-017-5897-0. Epub 2017 May 30. Ann Surg Oncol. 2017. PMID: 28560600 Free PMC article. Clinical Trial.
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.
Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W, Waldschmidt D, Jacobasch L, Wilhelm M, Rau BM, Grützmann R, Weinmann A, Maschmeyer G, Pelzer U, Stieler JM, Striefler JK, Ghadimi M, Bischoff S, Dörken B, Oettle H, Riess H. Sinn M, et al. J Clin Oncol. 2017 Oct 10;35(29):3330-3337. doi: 10.1200/JCO.2017.72.6463. Epub 2017 Aug 17. J Clin Oncol. 2017. PMID: 28817370 Clinical Trial.
Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).
Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, Enzinger PC, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Gunderson LL, Goldberg RM, Venook AP, Ilson D, O'Reilly E, Ciombor K, Berg DJ, Meyerhardt J, Mayer RJ. Fuchs CS, et al. J Clin Oncol. 2017 Nov 10;35(32):3671-3677. doi: 10.1200/JCO.2017.74.2130. Epub 2017 Oct 4. J Clin Oncol. 2017. PMID: 28976791 Free PMC article. Clinical Trial.
Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial.
Noordman BJ, Verdam MGE, Lagarde SM, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch OR, Ten Kate FJW, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A, Sprangers MAG, van Lanschot JJB. Noordman BJ, et al. J Clin Oncol. 2018 Jan 20;36(3):268-275. doi: 10.1200/JCO.2017.73.7718. Epub 2017 Nov 21. J Clin Oncol. 2018. PMID: 29161204 Clinical Trial.
Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01).
Penniment MG, De Ieso PB, Harvey JA, Stephens S, Au HJ, O'Callaghan CJ, Kneebone A, Ngan SY, Ward IG, Roy R, Smith JG, Nijjar T, Biagi JJ, Mulroy LA, Wong R; TROG 03.01/CCTG ES.2 group. Penniment MG, et al. Lancet Gastroenterol Hepatol. 2018 Feb;3(2):114-124. doi: 10.1016/S2468-1253(17)30363-1. Epub 2017 Dec 14. Lancet Gastroenterol Hepatol. 2018. PMID: 29248399 Clinical Trial.
Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database.
Rajyaguru DJ, Borgert AJ, Smith AL, Thomes RM, Conway PD, Halfdanarson TR, Truty MJ, Kurup AN, Go RS. Rajyaguru DJ, et al. J Clin Oncol. 2018 Feb 20;36(6):600-608. doi: 10.1200/JCO.2017.75.3228. Epub 2018 Jan 12. J Clin Oncol. 2018. PMID: 29328861
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators. Cats A, et al. Lancet Oncol. 2018 May;19(5):616-628. doi: 10.1016/S1470-2045(18)30132-3. Epub 2018 Apr 9. Lancet Oncol. 2018. PMID: 29650363 Clinical Trial.

References

1. Penniment MG, De Ieso PB, Harvey JA, et al. Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: A multicentre randomised controlled trial (TROG 03.01). Lancet Gastroenterol Hepatol 2018;3:114–124. - PubMed
1. Noordman BJ, Verdam MGE, Lagarde SM, et al. Effect of neoadjuvant chemoradiotherapy on health-related quality of life in esophageal or junctional cancer: Results from the randomized CROSS trial. J Clin Oncol 2018;36:268–275. - PubMed
1. Fuchs CS, Niedzwiecki D, Mamon HJ, et al. Adjuvant chemoradiotherapy with epirubicin, cisplatin, and fluorouracil compared with adjuvant chemoradiotherapy with fluorouracil and leucovorin after curative resection of gastric cancer: Results from CALGB 80101 (Alliance). J Clin Oncol 2017;35:3671–3677. - PMC - PubMed
1. Cats A, Jansen EPM, van Grieken NCT, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): An international, open-label, randomised phase 3 trial. Lancet Oncol 2018;19:616–628. - PubMed
1. Sinn M, Bahra M, Liersch T, et al. CONKO-005: Adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: A multicenter randomized phase III trial. J Clin Oncol 2017;35:3330–3337. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Grants and funding

P30 CA072720/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Gastrointestinal Cancers-Carving Out the Optimal Local Therapies in the Gastrointestinal Tract

Affiliations

Gastrointestinal Cancers-Carving Out the Optimal Local Therapies in the Gastrointestinal Tract

Authors

Affiliations

Erratum in

Conflict of interest statement

Comment on

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical